|
gptkbp:instance_of
|
gptkb:Company
|
|
gptkbp:bfsLayer
|
5
|
|
gptkbp:bfsParent
|
gptkb:Avapritinib
gptkb:Pralsetinib
|
|
gptkbp:acquisition
|
gptkb:Loxo_Oncology
|
|
gptkbp:can_lead_to
|
gptkb:Avapritinib
gptkb:Pralsetinib
|
|
gptkbp:ceo
|
Christine Carr
Amit K. Munshi
|
|
gptkbp:clinical_trial
|
gptkb:healthcare_organization
Phase 1
Phase 2
Phase 3
Phase 3 trials
solid tumors
Phase 1 trials
Phase 2 trials
late-stage
early-stage
|
|
gptkbp:collaborations
|
gptkb:Harvard_University
gptkb:Massachusetts_Institute_of_Technology
gptkb:Foundation_Medicine
gptkb:Novartis
|
|
gptkbp:employees
|
200+
over 300
|
|
gptkbp:focus
|
targeted therapies
|
|
gptkbp:founded
|
gptkb:2008
|
|
gptkbp:founder
|
gptkb:Nina_Shaw
Amit K. Munshi
|
|
gptkbp:governed_by
|
gptkb:Dr._Michael_J._O'_Connor
Dr. Jennifer A. Kwan
|
|
gptkbp:head_coach
|
Dr. David A. Meeker
|
|
gptkbp:headquarters
|
gptkb:Cambridge,_Massachusetts
|
|
gptkbp:healthcare
|
gptkb:2020
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Blueprint Medicines Corporation
|
|
gptkbp:investment
|
$1 billion
|
|
gptkbp:language_of_instruction
|
multiple drug candidates
multiple candidates
|
|
gptkbp:market_cap
|
approximately $1.5 billion
$3 billion
|
|
gptkbp:partnership
|
gptkb:Incyte_Corporation
gptkb:Merck
gptkb:temple
gptkb:Johnson_&_Johnson
gptkb:Zymeworks
gptkb:Takeda_Pharmaceutical_Company
gptkb:Acorda_Therapeutics
gptkb:Sanofi
gptkb:Boehringer_Ingelheim
gptkb:Bristol-Myers_Squibb
gptkb:Pfizer
gptkb:Regeneron_Pharmaceuticals
gptkb:Merck_&_Co.
gptkb:Roche
gptkb:Amgen
gptkb:Gilead_Sciences
gptkb:Eli_Lilly_and_Company
gptkb:Vertex_Pharmaceuticals
gptkb:Abb_Vie
gptkb:Celgene
gptkb:Sarepta_Therapeutics
gptkb:Novartis
gptkb:Nant_Kwest
gptkb:Celerion
gptkb:Blueprint_Medicines_Foundation
|
|
gptkbp:products
|
gptkb:BLU-554
gptkb:BLU-667
gptkb:Pralsetinib
gptkb:Ayvakit
gptkb:BLU-782
|
|
gptkbp:regulatory_compliance
|
gptkb:Dr._John_D._Mc_Carthy
gptkb:FDA
gptkb:EMA
|
|
gptkbp:research
|
Dr. R. Scott Mc Kinney
|
|
gptkbp:research_areas
|
oncology
rare diseases
hematology
|
|
gptkbp:research_focus
|
gptkb:healthcare_organization
genetic diseases
genetic drivers of cancer
|
|
gptkbp:symbol
|
BPMC
|
|
gptkbp:traded_on
|
gptkb:NASDAQ
|
|
gptkbp:website
|
blueprintmedicines.com
www.blueprintmedicines.com
|